|  |  | 

India Top Headlines

Covid-19 Vaccine for October-November: Adar Poonawalla to Naveen Patnaik | India News


BHUBANESWAR: Serum Institute of India, the world’s largest vaccine maker by volume, is hoping to develop a Covid-19 vaccine by October / November this year, its CEO Adar Poonawala said on Wednesday.
It has partnered with the biopharmaceutical company AstraZeneca to manufacture the candidate Covid-19 candidate vaccine developed by the University of Oxford.
It also got the go-ahead from DCGI to make its own locally developed pneumococcal vaccine.
Poonawalla, during an interaction with Odisha Prime Minister Naveen Patnaik, via video conference, expressed optimism that the Covid-19 vaccine could be ready by October-November this year and that the next phase of the trial can begin. in mid-August in India.
According to a press release published by the Prime Minister’s office, Poonawalla has reported that the Oxford University vaccine has shown promising results in the first phase of the trial.
“In India, the next test phase will start in mid-August and the vaccine will be ready by October-November this year,” he said in a video clip released by the CMO.
Poonawala further said that the Indian Whey Institute (SII) and the state government can be in contact with each other and carry out the collaboration once the vaccines are clean and ready.
Patnaik expressed his happiness that IBS has partnered with the University of Oxford to develop the Covid vaccine. She also congratulated Poonawala on the recent promising results published in Lancet on the Covid vaccine.
The prime minister sought his cooperation to keep Odisha a priority for vaccination once necessary authorizations are obtained. “The state government will contact the Serum Institute for this purpose,” said Patnaik.
Patnaik also applauded Poonawalla’s philanthropic activities and foresight as he dealt with various research institutions around the world to develop a vaccine for Covid-19.
Meanwhile, the selection process for human clinical trials of the Covid-19 vaccine developed in India has already started at an institute based in Bhubaneswar, one of 12 centers selected by ICMR to carry out phase one and two of the process, said a senior official.
Human trials of the BBV152 Covid or Covaxin vaccine are being carried out in a special laboratory established at the Institute of Medical Sciences and SUM Hospital (IMS & SUM), the facility official said here.
“The selection process for selecting volunteers for the vaccine trial is in full swing. The response from potential volunteers is very encouraging,” said Dr. E Venkat Rao, principal investigator of the trial process and professor of medicine. community in the hospital. he said to PTI.
The health profiles of potential volunteers who have registered are being thoroughly examined and their samples are being sent to the designated laboratory in New Delhi, he said, adding that after receiving the reports, the selected volunteers will receive the vaccine according to the guidelines. prescribed. .

Reference page